Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Summary

This is a Phase 1/2, open label, multi-centre study to assess the safety, tolerability, PD, and efficacy of adjuvant immunotherapy EVX-02 vaccine and anti-PD-1 (Nivolumab) in patients who have had a complete resection of a Stage IIIB/IIIC/IIID or Stage IV melanoma who are at high risk of recurrence.

Timeline

Start

2020-07-13

Primary completion

2023-02-28

Completion

2023-03-28

Outcome

Outcome not reported

Stopped: “Based on the promising interim results of study part 1, it was decided to further accelerate the development of the 2nd generation DNA plasmid immunotherapy. Therefore enrolment of patients was completed after study part 1”

Drugs

Indications